Evidence map›Paper›PMID 39289534›Full record

ArticleScientific reports2024

Real-world study on the efficacy and safety of different treatment regimens in treatment-naïve CHB patients with high viral load.

Xue Wu, Qin Yan, Chunmei Jiang, Rongshan Fan, Sheling Li

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. [Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xue WuDepartment of Infectious Disease, Shenzhen Nanshan People's Hospital, No. 89, Taoyuan Road, Nanshan District, Shenzhen, Shenzhen, 518052, Guangdong Province Shenzhen, China.
Qin YanDepartment of Infectious Disease, Shenzhen Nanshan People's Hospital, No. 89, Taoyuan Road, Nanshan District, Shenzhen, Shenzhen, 518052, Guangdong Province Shenzhen, China. wjd1415@tmu.edu.cn.
Chunmei JiangDepartment of Infectious Disease, Shenzhen Longhua District People's Hospital, Shenzhen city, Shenzhen, Guangdong, China.
Rongshan FanDepartment of Infectious Disease, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, Guangdong, China.
Sheling LiDepartment of Infectious Disease, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evaluate the real-world effectiveness and safety of different treatment regimens for treatment-naïve high viral load chronic hepatitis B (CHB) patients. Between January 2021 and August 2022, CHB patients with HBV DNA ≥ 10

Indexed as

Antiviral AgentsHepatitis B, ChronicHepatitis B virusViral LoadAdultDNA, ViralDrug Therapy, CombinationFemaleHepatitis B e AntigensHumansMaleMiddle AgedRetrospective StudiesTenofovirTreatment OutcomeAntiviral AgentsDNA, ViralHepatitis B e AntigensTenofovirHepatitis B, ChronicNucleos(t)ide analoguesViral loadVirologic Response

Identifiers

PMID39289534
PMCPMC11408625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.